|
|
Article: Eli Lilly's Ruboxistaurin, The First Disease-Modifying Agent for Use In Distal Symmetrical Polyneuropathy, will Dominate the Diabetic Neuropathy Drug Market; Ruboxistaurin Will Attain Nearly Two-Thirds of Market Share By 2011, According to a New Report from Decision Resources.
- Article from:
- PR Newswire
- Article date:
- December 16, 2002
CopyrightCOPYRIGHT 2002 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
WALTHAM, Mass. -- WALTHAM, Mass., Dec. 16 /PRNewswire/ -- Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, forecasts that Eli Lilly's ruboxistaurin, the first disease-modifying agent for use in distal symmetrical polyneuropathy (DSP), will dominate the diabetic neuropathy drug market. Ruboxistaurin will attain nearly two-thirds of market share by 2011, according to a new Pharmacor report entitled Diabetic Neuropathy.
(Photo: http://www.newscom.com/cgi-bin/prnh/20000303/DECISION )
"The introduction of ruboxistaurin marks the debut of a disease-modifying agent on the ...